Thank you for your interest in this product.
Please provide us with your contact information and your local representative
will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to º£½ÇÆÆ½â°æ Technologies Canada Inc. and its subsidiaries and affiliates (“º£½ÇÆÆ½â°æâ€) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
This site is protected by reCAPTCHA and the Ìý²¹²Ô»åÌýÌý²¹±è±è±ô²â.
The UCHT2 antibody reacts with CD5, an ~67 kDa single-chain type I glycoprotein and member of the scavenger receptor superfamily, which is constitutively expressed on thymocytes, T cells, B cell subsets, peripheral blood dendritic cells and some leukemia and lymphoma cells, including chronic B lymphocytic leukemia (B-CLL) cells. CD5 is expressed at low levels on thymocytes and at high density on mature T cells. Putative ligands include CD5L and CD72. CD5 modulates T and B cell receptor signaling, thymocyte maturation, and T cell/B cell interactions via its physical and functional associations with the T cell receptor/CD3 complex and the B cell receptor. Studies with CD5 knockout mice indicate that CD5 negatively regulates antigen receptor-mediated signaling in thymocytes and mature T cells. The UCHT2 antibody binds to epitope 2 located in the extracellular domain of CD5.
(A) Flow cytometry analysis of human buffy coat nucleated cells labeled with Anti-Human CD5 Antibody, Clone UCHT2, APC and Anti-Human CD20 Antibody, Clone 2H7, Alexa Fluor® 488 (Catalog #60008AD).
(B) Flow cytometry analysis of human buffy coat nucleated cells labeled with a mouse IgG1, kappa APC isotype control antibody and Anti-Human CD20 Antibody, Clone 2H7, Alexa Fluor® 488.
(C) Flow cytometry analysis of human buffy coat nucleated cells processed with the EasySepâ„¢ HLA Whole Blood CD3 Positive Selection Kit and labeled with Anti-Human CD5 Antibody, Clone UCHT2, APC. Histograms show labeling of buffy coat nucleated cells (Start) and isolated cells (Isolated). Labeling of start cells with a mouse IgG1, kappa APC isotype control antibody is shown (solid line histogram).
Figure 2. Data for Biotin-Conjugated
(A) Flow cytometry analysis of human buffy coat nucleated cells labeled with Anti-Human CD5 Antibody, Clone UCHT2, Biotin followed by streptavidin (SAV) APC and Anti-Human CD20 Antibody, Clone 2H7, PE (Catalog #60008PE). (B) Flow cytometry analysis of human buffy coat nucleated cells labeled with a mouse IgG1, kappa biotin isotype control antibody followed by streptavidin (SAV) APC and Anti-Human CD20 Antibody, Clone 2H7, PE. (C) Flow cytometry analysis of human buffy coat nucleated cells processed with the EasySep™ HLA CD3 Positive Selection Kit and labeled with Anti-Human CD5 Antibody, Clone UCHT2, Biotin followed by streptavidin (SAV) APC. Histograms show labeling of buffy coat nucleated cells (Start) and isolated cells (Isolated). Labeling of start cells with a mouse IgG1, kappa biotin isotype control antibody followed by SAV APC is shown (open histogram).
Figure 3. Data for FITC-Conjugated
(A) Flow cytometry analysis of human buffy coat nucleated cells labeled with Anti-Human CD5 Antibody, Clone UCHT2, FITC and Anti-Human CD20 Antibody, Clone 2H7, APC (Catalog #60008AZ).
(B) Flow cytometry analysis of human buffy coat nucleated cells labeled with a mouse IgG1, kappa FITC isotype control antibody and Anti-Human CD20 Antibody, Clone 2H7, APC.
(C) Flow cytometry analysis of human buffy coat nucleated cells processed with the EasySepâ„¢ HLA CD3 Positive Selection Kit and labeled with Anti-Human CD5 Antibody, Clone UCHT2, FITC. Histograms show labeling of buffy coat nucleated cells (Start) and isolated cells (Isolated). Labeling of start cells with a mouse IgG1, kappa FITC isotype control antibody is shown (solid line histogram).
Figure 4. Data for PE-Conjugated
(A) Flow cytometry analysis of human buffy coat nucleated cells labeled with Anti-Human CD5 Antibody, Clone UCHT2, PE and Anti-Human CD20 Antibody, Clone 2H7, APC (Catalog #60008AZ).
(B) Flow cytometry analysis of human buffy coat nucleated cells labeled with a mouse IgG1, kappa PE isotype control antibody and Anti-Human CD20 Antibody, Clone 2H7, APC.
(C) Flow cytometry analysis of human buffy coat nucleated cells processed with the EasySepâ„¢ HLA CD3 Positive Selection Kit and labeled with Anti-Human CD5 Antibody, Clone UCHT2, PE. Histograms show labeling of buffy coat nucleated cells (Start) and isolated cells (Isolated). Labeling of start cells with a mouse IgG1, kappa PE isotype control antibody is shown (solid line histogram).
Figure 5. Data for Unconjugated
Flow cytometry analysis of human peripheral blood mononuclear cells (PBMCs) labeled with Anti-Human CD5 Antibody, Clone UCHT2, followed by Goat Anti-Mouse IgG (H+L) Antibody, Polyclonal, FITC (Catalog #60138FI) (filled histogram), or a mouse IgG1, kappa isotype control antibody, followed by Goat Anti-Mouse IgG (H+L) Antibody, Polyclonal, FITC (solid line histogram).
Figure 6. Data for PerCP-Cy55-Conjugated
Flow cytometry analysis of human peripheral blood mononuclear cells (PBMCs) labeled with Anti-Human CD5 Antibody, Clone UCHT2, PerCP-Cy5.5 (filled histogram) or a mouse IgG1, kappa isotype control antibody, PerCP-Cy5.5 (solid line histogram).
This product is designed for use in the following research area(s) as part
of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we
offer to support each research area.
Mouse monoclonal IgG1, kappa isotype control antibody
Item added to your cart
Anti-Human CD5 Antibody, Clone UCHT2
Quality Statement:
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT º£½ÇÆÆ½â°æ, REFER TO WWW.º£½ÇÆÆ½â°æ.COM/COMPLIANCE.